<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516709</url>
  </required_header>
  <id_info>
    <org_study_id>CT003</org_study_id>
    <nct_id>NCT02516709</nct_id>
  </id_info>
  <brief_title>Linear Source Registry for Prostate Cancer</brief_title>
  <acronym>CaRePC</acronym>
  <official_title>CivaString Registry for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry is being conducted to provide long term analysis on the use of the linear
      Civastring source for prostate cancer. Prospective data collection will record and
      demonstrate biochemical response rates. Long term side effects and adverse events will be
      monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Biochemical Response Rate (PSA)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects (IPSS, IIEF, RFAS score)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Linear LDR Source</intervention_name>
    <description>The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients currently indicated for brachytherapy, implanted with the linear LDR source for
        prostate cancer with a life expectancy greater than 5 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Plans to remain in care of enrolling physician for 5 years

          -  &gt; 5 years life expectancy

          -  Signed informed consent

          -  Enrolled within 6 weeks of implant or within 365 days of prior implant

        Exclusion Criteria:

          -  Not willing or able to comply with protocol visit schedule
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristy Perez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CivaTech Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Solimando</last_name>
    <phone>919-314-5515</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Rath, Rn</last_name>
    </contact>
    <investigator>
      <last_name>Richard Stock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Researcch</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Moclair, RN</last_name>
    </contact>
    <investigator>
      <last_name>Jed Kaminetsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>August 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
